周围神经旁移植自体髓核对大鼠疼痛行为的影响

目的　探讨髓核在坐骨神经痛发病机制中的作用。方法　选择 16只SD雄性大鼠随机分为两组 ,分别将自体尾椎髓核混悬液注射到腰椎硬膜外腔或坐骨神经周围。测定其后肢机械刺激缩爪阈值。结果　在没有明显机械压迫下 ,腰椎硬膜外腔的髓核使大鼠后肢产生明显的痛觉过敏反应 ,坐骨神经旁的髓核不能使大鼠产生上述变化。结论　与髓核相关的炎症的介质是引起坐骨神经痛的原因之一 ,神经根缺乏神经外膜保护是引起疼痛的解剖学基础。     

鞘内注射胍丁胺对骨癌痛大鼠痛觉及脊髓背角NMDA受体1表达的影响

目的 观察鞘内注射胍丁胺对骨癌痛大鼠痛觉及脊髓背角NMDA受体1(NR1)表达的影响.方法 成年雌性Wistar大鼠,体重180～220 g,假模型组(A组,n=14)接种PBS液,骨癌痛模型制作成功大鼠随机分为三组,其中B组(n=14)不行鞘内注射,另两组分别鞘内注射生理盐水10 μl(C组,n=14)和胍丁胺160 mg/kg(D组,n=14).用von Frey丝测定大鼠机械缩足反射阈值(MWT),于鞘内注射后120min用Western blot方法测定脊髓背角NR1蛋白的表达.结果 建模7d后B、C和D组大鼠MWT明显低于A组(P＜0.05),鞘内注射胍丁胺后D组MWT显著高于B、C组(P＜0.05).鞘内给药120 min后B、C、D组NR1蛋白的相对表达量明显高于A组(P＜0.05),D组明显低于B、C组(P＜0.05).结论 鞘内注射胍丁胺可通过抑制大鼠脊髓背角NR1的表达减轻胃癌痛.     

鞘内注射Roscovitine对小鼠骨癌痛行为学的影响

目的 探讨鞘内给予细胞周期依赖性激酶5(cyclin-dependent kinases,Cdk5)特异性拮抗剂Roscovitine对小鼠骨癌痛行为学的影响.方法 24只C3H/Hej 小鼠采用随机数字表法随机分为3组,S组(假手术后14 d+溶媒)、C组(接种后14d+溶媒)、R组(接种后14 d+Roscovitine),每组8只.C组和R组将含2×105个纤维肉瘤NCTC 2472细胞的最小必需培养基(α-MEM)20μl注射到小鼠右侧股骨远端骨髓腔内,制作骨癌痛模型.S组只注入不含肿瘤细胞的α-MEM.术后14 d,R组小鼠鞘内注射含有20μg Roscovitine的二甲基亚砜(DMSO)5μl,C组及S组小鼠鞘内注DMSO 5 μl.观察给药前及给药后1、6、24、48、72 h检测小鼠痛行为学的变化:机械缩足阈值(paw uithdrawal mechanical threshold,PMWT)和热缩足潜伏期(Paw withdrawal thermal latency,PWTL).结果 各组术前基础机械缩足阈值及热缩足潜伏期比较差异无统计学意义(P＞0.05).接种后7 d,C组PMWT(1.08±0.24)g,与S组(1.85±0.28)g相比明显降低(P＜0.05);接种后10 d,C组PTWL(12.7±1.4)s较S组(18.6±2.1)s明显缩短(P＜0.05),C组小鼠的痛行为学随时间逐渐加重,与S组小鼠比较差异有统计学意义(P＜0.05);与C组及给药前基础值相比,鞘内注射Roscovitine 20μg后6 h PMWT(0.70±0.19)g显著增加(P＜0.05),PTWL(14.16±1.07)s显著延长(P＜0.05),并随时间逐渐增加,12 h达最大值,后逐渐降低,72 h降低到C组水平.结论 鞘内注射Roscovitine可有效缓解小鼠骨癌痛.     

鞘内注射JNK特异性抑制剂SP600125对CCI大鼠痛行为的影响

目的 观察鞘内注射c-Jun氨基末端蛋白激酶(c-Jun N-terminal protein kinase,JNK)特异性抑制剂SP600125对慢性压榨性损伤(chronic constriction injury,CCI)大鼠痛行为的影响.方法 雄性sD大鼠40只,随机分为5组(n=8). SP5组:CCI模型,鞘内注射SP600125 5μg;SP25组:CCI模型,鞘内注射SP600125 25 μg;SP50组:CCI模型,鞘内注射SP600125 50μg;DMSO组:CCI模型,鞘内注射2%二甲亚砜溶剂10 μl;Naive组:正常大鼠,鞘内注射SP600125 50μg.SP600125均溶于2%二甲亚砜10μl.CCI模型制作7 d后行鞘内注射,并测定大鼠机械缩足反射阈值(mechanical withdrawal threshold,MWT)及热缩足反射潜伏期(thermal withdrawal latency,TWL).结果 鞘内注射SP600125对正常大鼠的痛行为无影响.鞘内注射一定剂量SP600125能减轻CCI大鼠的机械痛敏及热痛敏.结论 鞘内注射一定剂量的SP600125能够减轻CCI大鼠的机械痛敏及热痛敏.     

不同剂量驱动蛋白17反义寡核苷酸鞘内注射对骨癌痛小鼠痛行为的影响

目的 通过鞘内注射不同剂量驱动蛋白17(kinesin superfamily 17,KIF17)反义寡核苷酸,研究其在骨癌痛小鼠疼痛发生中的作用. 方法 55只雄性C3H/HeJ小鼠,4周～6周龄,体重20 g～25 g.用随机数字表法分为骨癌组(A组,41只)和假手术组(S组,14只).A组小鼠右侧股骨骨髓腔内注射20μl含约2×105个纤维肉瘤细胞(NCTC2472)的最小必须培养基(α-minimal essence medium,α-MEM)以制备骨癌痛模型,S组小鼠右侧股骨骨髓腔内注射等体积不含肿瘤细胞的α-MEM.各组小鼠于接种前(base)及接种后第4、7、10、14天进行痛行为学测试,包括自发抬足次数(the number of spontaneous flinches,NSF)和机械缩足反射阈值(paw withdrawal mechanical threshold,PWMT).每组每个时间点各取1只小鼠断头处死,取L3-5脊髓,用免疫印迹法(Western blot)测定KIF17蛋白含量.在接种后第14天,再将剩余A组小鼠按随机数字表法分为KIF17反义寡核苷酸2.5 μg组(A1组)、KIF17反义寡核苷酸5.0 μg组(A2组)、KIF17反义寡核苷酸10.0 μg组(A3组)以及对照组(AC组),每组9只.A1组～A3组小鼠分别鞘内给予相应剂量KIF17反义寡核苷酸,S组和AC组小鼠鞘内给予生理盐水,注药容积均为5μl.给药结束后2、12、24、36、48 h每个时间点取1只小鼠处死,再行痛行为学测试和脊髓水平KIF17蛋白含量. 结果 与S组[(2.15±0.49)次、(1.80±0.39)g]和基础值[(2.08±0.34)次、(1.88±0.35)g]比较,接种后第14天,A组小鼠NSF显著增加[(11.95±0.78)次],PWMT显著降低[(0.34±0.11)g](P＜0.05);同时A组小鼠脊髓水平KIF17表达增多;与AC组和给药前比较,A1组小鼠在给药后2、12h和24 h,NSF[2 h(4.80±0.40)次]减少,PWMT[2 h(0.95±0.33)g]升高(P＜0.05),A2组和A3组小鼠在给药后2、12、24 h和36 h,NSF[2 h(2.35±0.26)、(2.53±0.21)次]减少,PWMT[2 h(1.70±0.32)、(1.73±0.40)g]升高(P＜0.05),且与A1组比较,A2组和A3组小鼠痛行为学的改善更明显,A2组与A3组各时间点小鼠NSF和PWMT比较,差异无统计学意义(P＞0.05);给药后2h,A1组～A3组小鼠脊髓水平KIF17表达减少. 结论 骨癌痛小鼠脊髓水平KIF17表达上调,鞘内给予KIF17反义寡核苷酸能有效改善骨癌痛小鼠的痛行为学,其镇痛效果和作用时间与剂量有关.     

鞘内注射JNK特异性抑制剂SP600125对CCI大鼠痛行为的影响

Objective To observe the effect of intrathecal administration of SP600125 on both MWT and TWL of rats after chronic constriction injury (CCI) of the sciatic nerve. Methods 40 male SD rats were randomized to deride into 5 groups (n=8). Rats in group SP5 received SP600125 5 μg after CCI; rats in group SP25 received SP600125 25 μg after CCI; rats in group SP50 received SP600125 50 μg after CCI; rats in group DMSO received 2% DMSO 10 μl after CCI; rats in group Naive received SP600125 50 μg without sciatic nerve injury. SP600125 was dissolved in 10 μl 2%DMSO solvent. On the 7th day after CCI, MWT and TWL were determined with yon Frey filaments and thermal radiation apparatus repectively after intrathecal administration of SP600125. Results Intrathecal administration certain dosage of SP600125 could attenuate the established mechanical allodynia and thermal hyperalgesia induced by CCI rather than normal rats. Conclusion Intrathecal administration certain dosage of SP600125 could attenuate the established mechanical allodynia and thermal hyperalgesia induced by CCI.     

鞘内注射JNK特异性抑制剂SP600125对CCI大鼠痛行为的影响

Objective To observe the effect of intrathecal administration of SP600125 on both MWT and TWL of rats after chronic constriction injury (CCI) of the sciatic nerve. Methods 40 male SD rats were randomized to deride into 5 groups (n=8). Rats in group SP5 received SP600125 5 μg after CCI; rats in group SP25 received SP600125 25 μg after CCI; rats in group SP50 received SP600125 50 μg after CCI; rats in group DMSO received 2% DMSO 10 μl after CCI; rats in group Naive received SP600125 50 μg without sciatic nerve injury. SP600125 was dissolved in 10 μl 2%DMSO solvent. On the 7th day after CCI, MWT and TWL were determined with yon Frey filaments and thermal radiation apparatus repectively after intrathecal administration of SP600125. Results Intrathecal administration certain dosage of SP600125 could attenuate the established mechanical allodynia and thermal hyperalgesia induced by CCI rather than normal rats. Conclusion Intrathecal administration certain dosage of SP600125 could attenuate the established mechanical allodynia and thermal hyperalgesia induced by CCI.     

鞘内注射JNK特异性抑制剂SP600125对CCI大鼠痛行为的影响

Objective To observe the effect of intrathecal administration of SP600125 on both MWT and TWL of rats after chronic constriction injury (CCI) of the sciatic nerve. Methods 40 male SD rats were randomized to deride into 5 groups (n=8). Rats in group SP5 received SP600125 5 μg after CCI; rats in group SP25 received SP600125 25 μg after CCI; rats in group SP50 received SP600125 50 μg after CCI; rats in group DMSO received 2% DMSO 10 μl after CCI; rats in group Naive received SP600125 50 μg without sciatic nerve injury. SP600125 was dissolved in 10 μl 2%DMSO solvent. On the 7th day after CCI, MWT and TWL were determined with yon Frey filaments and thermal radiation apparatus repectively after intrathecal administration of SP600125. Results Intrathecal administration certain dosage of SP600125 could attenuate the established mechanical allodynia and thermal hyperalgesia induced by CCI rather than normal rats. Conclusion Intrathecal administration certain dosage of SP600125 could attenuate the established mechanical allodynia and thermal hyperalgesia induced by CCI.     

鞘内注射JNK特异性抑制剂SP600125对CCI大鼠痛行为的影响

Objective To observe the effect of intrathecal administration of SP600125 on both MWT and TWL of rats after chronic constriction injury (CCI) of the sciatic nerve. Methods 40 male SD rats were randomized to deride into 5 groups (n=8). Rats in group SP5 received SP600125 5 μg after CCI; rats in group SP25 received SP600125 25 μg after CCI; rats in group SP50 received SP600125 50 μg after CCI; rats in group DMSO received 2% DMSO 10 μl after CCI; rats in group Naive received SP600125 50 μg without sciatic nerve injury. SP600125 was dissolved in 10 μl 2%DMSO solvent. On the 7th day after CCI, MWT and TWL were determined with yon Frey filaments and thermal radiation apparatus repectively after intrathecal administration of SP600125. Results Intrathecal administration certain dosage of SP600125 could attenuate the established mechanical allodynia and thermal hyperalgesia induced by CCI rather than normal rats. Conclusion Intrathecal administration certain dosage of SP600125 could attenuate the established mechanical allodynia and thermal hyperalgesia induced by CCI.     

鞘内注射JNK特异性抑制剂SP600125对CCI大鼠痛行为的影响

Objective To observe the effect of intrathecal administration of SP600125 on both MWT and TWL of rats after chronic constriction injury (CCI) of the sciatic nerve. Methods 40 male SD rats were randomized to deride into 5 groups (n=8). Rats in group SP5 received SP600125 5 μg after CCI; rats in group SP25 received SP600125 25 μg after CCI; rats in group SP50 received SP600125 50 μg after CCI; rats in group DMSO received 2% DMSO 10 μl after CCI; rats in group Naive received SP600125 50 μg without sciatic nerve injury. SP600125 was dissolved in 10 μl 2%DMSO solvent. On the 7th day after CCI, MWT and TWL were determined with yon Frey filaments and thermal radiation apparatus repectively after intrathecal administration of SP600125. Results Intrathecal administration certain dosage of SP600125 could attenuate the established mechanical allodynia and thermal hyperalgesia induced by CCI rather than normal rats. Conclusion Intrathecal administration certain dosage of SP600125 could attenuate the established mechanical allodynia and thermal hyperalgesia induced by CCI.     

p38丝裂原活化蛋白激酶与病理性疼痛

病理性疼痛病理机制复杂,临床常用的药物治疗效果差。p38丝裂原活化蛋白激酶可通过多种方式影响疼痛的形成与维持。动物试验及部分临床研究初步表明,p38MAPK特异性的抑制剂用于治疗病理性疼痛可能具有良好的应用前景。     

脊髓小胶质细胞内信号p38丝裂原活化蛋白激酶在神经病理性疼痛的作用

证据表明小胶质细胞在神经病理性疼痛中扮演着重要的角色.神经损伤后,小胶质细胞内p38丝裂原活化蛋白激酶(p38 mitogen activated protein kinase,p38MAPK)激活,致小胶质细胞产生各种生物活性物质,引发痛觉超敏.小胶质细胞内p38MAPK在神经病理性疼痛的发生和发展中起重要作用,p38MAPK及其亚型有望成为治疗神经病理性疼痛的新靶点.     

p16/p38 MAPK/p53/Wip1通路在乳腺癌发生、发展中的作用及其临床意义

目的 探讨p16/p38 MAPK/p53/Wip1通路在乳腺癌发生、发展中的作用及其临床意义.方法 应用免疫组织化学方法检测70例乳腺癌组织、癌旁组织、20例正常乳腺组织中Wip1、p53、p38 MAPK、p16蛋白的表达,并对Wip1蛋白高表达与p53、p38、p16蛋白表达进行相关分析.结果 3种组织中Wip1蛋白高表达率分别为62.9%(44/70)、2.9%(2/70)、0(0/20).乳腺癌组织比癌旁组织、正常乳腺组织明显升高(P＜0.01).Wip1蛋白高表达与p53、p38、p16蛋白表达呈负相关(P＜0.01,等级相关系数rs分别为-0.529、-0.626、-0.499).结论 p16/p38 MAPK/p53/Wip1是负反馈通路,它可能在乳腺癌发生发展中起重要作用.     

Improvement of Human Islet Cryopreservation by a p38 MAPK Inhibitor

The activation of p38 mitogen-activated protein kinase (MAPK) has been shown to cause ischemia/reperfusion injury of several organs used for transplantation and also to play a significant role in primary islet graft nonfunction. Activation of p38 MAPK may also occur during islet cryopreservation and thawing. In this study, a p38 MAPK inhibitor (p38IH) was applied to human islet cryopreservation to improve islet yield and quality after thawing. Under serum-free conditions, human islets were cryopreserved, thawed and cultured using our standard procedures. Three types of solutions were tested: conventional RPMI1640 medium (RPMI), a newly developed islet cryopreservation solution (ICS), and ICS supplemented with a p38IH, SD-282 (ICS-p38IH). Activation or inhibition of p38 MAPK was demonstrated by the diminished phosphorylation of HSP27 substrate. Islet recovery on day 2 after thawing was highest with ICS-p38IH and islet viability was not significantly different in the three groups. beta Cell numbers and function were the highest in islets cryopreserved with ICS-p38IH. Glucose-stimulated human C-peptide levels were 86% of that of the nonfrozen islets when measured 4 weeks after transplantation into NODscid mice. This improvement may provide an opportunity to establish islet banks and allow the use of cryopreserved islets for clinical transplantation.     

基于p38MAPK信号通路分析咪达唑仑对腰椎间盘突出症模型大鼠疼痛的影响CSCD

目的:探究基于p38MAPK信号通路分析咪达唑仑对腰椎间盘突出症模型大鼠疼痛的影响。方法:选取50只SPF级别SD健康大鼠,雌雄各半,随机分为正常组,模型组,低、中、高剂量组,模型组和低、中、高剂量组先建立腰椎间盘突出症模型。正常组、模型组大鼠腹腔注射生理盐水,低、中、高剂量组大鼠腹腔注射咪达唑仑,分别按30、60、90 mg/kg给药。采用酶联免疫吸检测大鼠血清中白细胞介素-1β(interleukin-1β,IL-1β)、肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)、5-羟色胺(5-hydroxytryptamine,5-HT)、β-内啡肽(β-endorphin,β-EP)、P物质(substance P,SP)、神经肽Y(neuropeptide Y,NPY)水平,采用Western blot检测各组大鼠组织中p38 MAPK,基质金属蛋白酶3(matrix metalloproteinase-3,MMP3)蛋白表达。结果:模型组大鼠TNF-α、IL-1β、β-EP水平较正常组高,5-HT水平低于正常组(P<0.05);低、中、高剂量组大鼠TNF-α、IL-1β、β-EP水平较模型组下降、5-HT水平升高(P<0.05)。模型组大鼠较正常组SP、NPY水平上升(P<0.05);低、中、高剂量组较模型组大鼠SP、NPY水平下降(P<0.05)。模型组较正常组大鼠p38 MAPK、MMP-3表达上升(P<0.05),低、中、高剂量较模型组大鼠p38 MAPK、MMP-3表达下降(P<0.05)。结论:咪达唑仑可以改善腰椎间盘突出症模型大鼠的免疫炎症反应,可能是通过p38MAPK信号通路调控来实现的。     

艾塞那肽通过p38MAPK通路对成骨细胞促增殖和抗凋亡的作用研究

目的探讨艾塞那肽通过p38MAPK通路对成骨细胞促增殖和抗凋亡的作用机制。方法将小鼠成骨细胞MC3T3-E1Subclone 14分为对照组、艾塞那肽组、棕榈酸钠组、棕榈酸钠组+艾塞那肽组,分别使用相应试剂培养48 h。通过CCK-8和流式细胞术检测细胞活力与凋亡。通过Western blot检测细胞中P38MAPK、Cyclin D1、Caspase-3的蛋白水平。结果艾塞那肽对正常细胞活力无显著影响(P0.05),棕榈酸钠组的细胞活力显著低于对照组(P0.01),艾塞那肽+棕榈酸钠组的细胞活力显著高于棕榈酸钠组(P0.01);艾塞那肽对正常细胞凋亡无显著影响(P0.05),棕榈酸钠组的细胞凋亡率显著高于对照组(P0.01),艾塞那肽+棕榈酸钠组的细胞凋亡率显著低于棕榈酸钠组(P0.01);艾塞那肽对正常细胞中P38MAPK、Cyclin D1和Caspase-3蛋白水平无明显影响(P0.05),棕榈酸钠组的P38MAPK和Caspase-3显著高于对照组而Cyclin D1显著低于对照组(P0.01),艾塞那肽+棕榈酸钠组的P38MAPK和Caspase-3显著低于棕榈酸钠组而Cyclin D1显著高于棕榈酸钠组(P0.01)。结论艾塞那肽可以通过p38MAPK通路,减少Caspase-3蛋白并上调Cyclin D1蛋白的表达,抑制高脂环境下成骨细胞的凋亡并提高细胞活力。     

p38MAPK信号转导通路在大鼠骨癌痛中的作用

目的 探讨p38丝裂原活化蛋白激酶(p38MAPK)信号转导通路在大鼠骨癌痛中的作用.方法 雌性sD大鼠56只,体重150～170 g,随机分为4组(n=14):生理盐水对照组(NS组)、骨癌痛组(BC组)、二甲基亚砜组(DMSO组)和p38MAPK抑制剂组(SB203580组).骨髓腔内注射Walker256细胞悬液制备大鼠骨癌痛模型,注射后10 d,DMSO组和SB203580组分别鞘内注射5%二甲基亚砜和SB203580(10 μg)10 μl.各组随机取8只大鼠,于注射Walker256细胞悬液前、注射后1、3、5、7、10 d,鞘内给药后1、3、6、12、24 h时采用von Frey纤维丝测定术侧后爪机械缩足反射阈值(MWT);各组余6只大鼠鞘内给药后6 h时取L_(4,5)脊髓,采用免疫组化法检测脊髓背角磷酸化环磷酸腺苷反应元件结合蛋白(pCREB)的表达水平.结果 骨髓腔内注射Walker256细胞悬液后7 d大鼠术侧后爪MWT开始降低,鞘内注射SB203580提高了MWT;骨髓腔内注射Walker256细胞悬液后脊髓背角pCREB表达上调,鞘内注射SB203580后脊髓背角pCREB表达下调.结论 鞘内注射SB203580可通过抑制脊髓背角pCREB的表达减轻骨癌痛;p38MAPK信号转导通路在骨癌痛中起重要作用.     

P38MAPK和P13K/Akt信号通路在大鼠糖尿病神经病理性疼痛中的交互作用

目的 观察p38MAPK和P13K/Akt信号通路在大鼠糖尿病神经病珲性疼痛中的交互作用.方法 Wistar大鼠腹腔单次注射链脲菌素65 mg/kg制作糖尿病神经病理痛模型.4周后用von frey纤维测双后足机械痛阈,痛阈明显下降为糖尿病神经病理性疼痛造模成功.将96只成模大鼠随机均分为三组:糖尿病神经病理痛组(D组),PI3K抑制药组(E组)和p38MAPK抑制药组(F组).另取同窝大鼠32只作为对照组(C组).成模后的每周周一,E组和F组大鼠分别静脉注射P13K抑制药Wortmannin 0.5 mg/kg和p38MAPK抑制药SB203580 1 mg/kg,直至处死大鼠.于给药前(T1)和给药后第2周末(T2)、第4周末(T3)、第6周末(T4)分别随机取8只大鼠,检测机械缩足反应阈值(MWT)、神经传导速度(NCV)、脊髓和背根神经节(DRG)磷酸化Akt(p-Akt)水平和磷酸化p38MAPK(p-p38MAPK)水平.结果 与C组比较,D、E和F组在T1～T4时MWT下降,NCV减慢,p-Akt和p-p38MAPK水平升高(P<0.05);与D组比较,E和F组在T2～T4时MWT升高,NCV增快,E和F组p-Akt明显下降,F组p-p38MAPK水平明显下降(P<0.05).结论 P38MAPK通过激活其下游的P13K/Akt信号通路参与了糖尿病大鼠神经病理痛的形成和维持.     

鞘内注射GDNF对神经病理性痛大鼠脊髓背角p38MAPK蛋白表达的影响

目的 评价鞘内注射胶质细胞源性神经营养因子(GDNF)对神经病理性痛大鼠脊髓背角p38丝裂原活化蛋白激酶(p38MAPK)蛋白表达的影响.方法 取鞘内置管成功的健康雄性SD大鼠120只,周龄6周,体重180～200 g,随机分为4组(n=30):对照组(C组)、假手术组(S组)、神经病理性痛组(P组)和GDNF组.采用结扎L5.6脊神经的方法建立大鼠神经病理性痛模型.C组不给予任何处理;S组只暴露脊神经,但不结扎;P组脊神经结扎后鞘内注射生理盐水10μl,隔日1次,连续14 d;GDNF组脊神经结扎后鞘内注射GDNF 2μg,用生理盐水稀释至10μl,隔日1次,连续14 d.分别于脊神经结扎后3、7和14 d时,取10只大鼠,测定机械痛阈,然后处死,取脊髓背角,分别采用免疫组化法和蛋白质印迹法测定p38MAPK蛋白的表达水平.结果 与S组比较,P组和GDNF组机械痛阈降低,脊髓背角p38MAPK蛋白表达上调(P＜0.05或0.01);与P组比较,GDNF组机械痛阈升高,脊髓背角p38MAPK蛋白表达下调(P＜0.05或0.01).结论 鞘内注射GDNF可通过抑制脊髓背角p38MAPK蛋白的表达减轻大鼠神经病理性痛.